Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5319 in MTAP-deleted Advanced Solid Tumors
NCT07128303Phase 1Recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2025
- Primary completion
- May 2028
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of GS-5319 in solid tumor (advanced stage) (4 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants With Adverse Events (AEs) and Serous Adverse Events (SAEs) up to 2 years, Percentage of Participants Experiencing Laboratory Abnormalities up to 2 years and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
GS-5319
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07128303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128303.